Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure

American Journal of Cardiology

Volumn 85, Issue 4, 2000, Pages 506-508

  Gold, Jeffrey ^a   Cullinane, Suzanne ^b   Chen, Jonathan ^b   Seo, Susan ^a   Oz, Mehmet C ^b   Oliver, Juan A ^a   Landry, Donald W ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; DOBUTAMINE; DOPAMINE; MILRINONE; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; VASOPRESSIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; URINE VOLUME; VASCULAR SMOOTH MUSCLE; VASODILATATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BLOOD PRESSURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPOTENSION; INJECTIONS, INTRAVENOUS; MILRINONE; MYOCARDIAL CONTRACTION; PHOSPHODIESTERASE INHIBITORS; PULMONARY WEDGE PRESSURE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 0033960832     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00783-3     Document Type: Article

References (20)

1. Colucci W.S., Denniss A.R., Quigg R.J., Ludmer P.L., Marsh J.D., Gauthier D.F. Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. J Clin Invest. 81:1988;1103-1110.
2. Uretsky B.F., Lawless C.E., Verbalis J.G., Valdes A.M., Kolesar J.A., Reddy P.S. Combined therapy with dobutamine and amrinone in severe heart failure. Chest. 92:1987;657-662.
3. Kauffman R.F., Schenck K.W., Utterback B.G., Crowe V.G., Cohen M.L. In vitro vascular relaxation by new inotropic agents relationship to phosphodiesterase inhibition and cyclic nucleotides . J Pharmacol Exp Ther. 242:1987;864-872.
4. Lugnier C., Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP role in vasodilatation . Eur Heart J. 14:1993;141-148.
5. DeGuzman N.T., Munoz O., Pamer R.F., Davolos D., Alousi A. Clinical evaluation of amrinone (A) - new inotropic agent. Circulation. 58:1978;19.
6. Zheng X., Ma S.J., Zhang T.H., Chen S.C. Plasma levels of cyclic nucleotides in congestive heart failure and their clinical implication. Int J Cardiol. 40:1993;7-15.
7. Ferry D.R., Kennedy G.T., Rourke R.A., Crawford M.H. Hemodynamic effects of prolonged intravenous therapy with enoximone in patients with severe congestive heart failure. J Cardiovasc Pharmacol. 11:1988;115-122.
8. Taylor S.H., Verma S.P., Hussain M., Reynolds G., Jackson N.C., Hafizullah M., Richmond A., Silke B. Intravenous amrinone in left ventricular failure complicated by acute myocardial infarction. Am J Cardiol. 56:1985;29B-32B.
9. Nambi P, Whitman M, Gessner G, Aiyar N, Crooke ST. Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci USA 1986;83:8492-1895.
10. Nambi P., Whitman M., Stassen F.L., Crooke S.T. Vascular vasopressin receptors mediate inhibition of beta adrenergic receptor-induced cyclic AMP accumulation. J Pharmacol Exp Ther. 237:1986;143-146.
11. Colucci W.S. In vivo studies of myocardial β-adrenergic receptor pharmacology in patients with congestive heart failure. Circulation. 82:(suppl I):1990;I44-I51.
12. Nakaoka H., Imataka K., Kitachara Y., Fujii J., Ishibashi M., Yamaji T. Relationship between plasma levels of atrial natriuretic peptide and cyclic guanosine monophosphate in patients with heart disease. Jpn Circ J. 52:1988;30-34.
13. Ebert T.J., Cowley A.W., Skelton M. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. J Clin Invest. 77:1986;1136-1142.
14. Goldsmith S.R., Francis G.S., Cowley A.W., Goldenberg I.F., Cohn J.N. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol. 8:1986;779-783.
15. 2-vasopressinergic receptors . Am J Physiol. 255:1988;H261-H265.
16. Boyle Q.A. III, Segel L.D. Direct cardiac effects of vasopressin and their reversal by a vascular antagonist. Am J Physiol. 251:1986;H734-H741.
17. Eckberg D.L., Drabinsky M., Braunwald E. Defective cardiac parasympathetic control in patients with heart failure. N Engl J Med. 2825:1971;877-883.
18. Ferguson D.W., Berg W.J., Roach P.J., Oren R.M., Mark A.L. Effects of heart failure on baroreflex control of sympathetic neural activity. Am J Cardiol. 69:1992;523-531.
19. Wagner H.N. Jr, Braunwald E. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest. 35:1956;1412-1418.
20. Edwards R.M., Rizna W., Kinter L.B. Renal microvascular effects of vasopressin and vasopressin antagonist. Am J Physiol. 256:1989;F274-F278.